Nectin-4 (NECTIN4) is a transmembrane protein overexpressed in various cancers, including urothelial, breast, and ovarian carcinomas, and correlates with poor prognosis . The NECTIN4 Antibody, Biotin conjugated, is a rabbit polyclonal antibody developed for research applications, leveraging biotin labeling for enhanced sensitivity in assays requiring avidin-biotin detection systems .
The antibody is primarily validated for ELISA to detect Nectin-4 in human samples . Its biotin conjugation enables compatibility with streptavidin-based detection systems, enhancing assay sensitivity. Potential applications include:
Biomarker analysis: Quantifying Nectin-4 expression in tumor tissues or sera to assess cancer progression.
Immunohistochemistry (IHC): Localizing Nectin-4 in tissue sections (requires appropriate secondary reagents).
Western blot: Detecting Nectin-4 in lysates, though optimization may be needed.
Nectin-4 is a validated target for antibody-drug conjugates (ADCs) like enfortumab vedotin (EV), approved for urothelial cancer . Overexpression of Nectin-4 correlates with tumor aggressiveness and poor survival , making it a critical biomarker for therapeutic strategies.
The antibody’s specificity for Nectin-4 aligns with research on next-generation ADCs, such as 9MW2821, which demonstrates superior efficacy and safety compared to EV in preclinical models . Its biotin labeling facilitates integration into assays for validating ADC binding or tumor targeting.
Nectin-4-targeted CAR-T cells, such as Nectin4-7.19 CAR-T, show promise in eradicating metastatic tumors in preclinical models . The antibody supports studies on CAR-T cell specificity and tumor antigen recognition.